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 Abstract 
Background 
Huntington’s disease is an autosomal-dominant neurodegenerative disease caused by 
a trinucleotide repeat (CAG) expansion in HTT, resulting in a mutant huntingtin protein.  
IONIS-HTTRx is an antisense oligonucleotide designed to inhibit HTT messenger RNA and 
thereby reduce levels of mutant huntingtin. 
 
Methods 
We conducted a randomized, double-blind, multiple-ascending-dose, phase 1/2a study 
in adult persons with early-manifest Huntington’s disease.  Participants received IONIS-
HTTRx or placebo (3:1) via bolus intrathecal administration every 4 weeks for 4 doses.  
Dose selection was guided by a preclinical model in mouse and monkey relating dose 
level to reduction in huntingtin.  The primary endpoint was safety.  The secondary 
endpoint was IONIS-HTTRx pharmacokinetics in cerebrospinal fluid.  Prespecified 
exploratory outcomes included the concentration of mutant huntingtin in cerebrospinal 
fluid. 
Results 
Of the 46 patients who enrolled in the study, 34 were randomized to receive IONIS-
HTTRx (10 to 120 mg) and 12 were randomized to receive placebo; each participant 
received all 4 doses and completed the study.  Adverse events were reported in 98% of 
patients with all being grade 1 or 2; no serious adverse events were seen in drug-
treated patients.  There were no clinically-relevant adverse laboratory parameter 
 changes.  Pre-dose (trough) cerebrospinal fluid concentrations of IONIS-HTTRx 
exhibited dose-dependence up to doses of 60 mg.  IONIS-HTTRx treatment resulted in 
dose-dependent reduction in cerebrospinal fluid mutant huntingtin (mean changes from 
baseline to endpoint of +9.8%, -19.9%, -25.0%, -27.5%, -42.4% and -37.7% for placebo, 
10-, 30-, 60-, 90- and 120-mg dose groups, respectively).   
Conclusions 
Intrathecal administration of IONIS-HTTRx to early HD patients was not accompanied by 
serious adverse events.  We observed dose-dependent reductions in levels of mutant 
huntingtin. 
(Funded by Ionis Pharmaceuticals and F. Hoffmann-La Roche Ltd; ClinicalTrials.gov 
NCT02519036) 
 
 Introduction 
Huntington’s disease (HD) is a progressive neurodegenerative disorder inherited as an 
autosomal dominant trait, with onset typically in mid-adult life and characterized by 
movement disorder, cognitive decline and behavioral symptoms.1  HD is caused by a 
CAG repeat expansion in the huntingtin (HTT) gene, which encodes huntingtin protein 
(HTT).2  The abnormal gene results in production of gene products including mutant 
huntingtin protein (mHTT) containing an expanded polyglutamine tract, which causes 
neuronal dysfunction and death, putatively through toxic gain-of-function mechanisms. 
3,4 Current treatments for HD are limited to symptomatic therapies, as no treatment has 
been shown to prevent onset or to slow progression.  Given the monogenic nature of 
HD, we sought to inhibit HTT expression and thus directly target the primary disease 
mechanism.5 
IONIS-HTTRx (also known as ISIS 443139 and RG6042; hereafter referred to as HTTRx) 
is a second-generation 2′-O-(2-methoxyethyl) (2′-O-MOE) antisense oligonucleotide 
designed to reduce levels of HTT messenger RNA (mRNA).  HTTRx binds to its cognate 
mRNA through Watson-Crick base-pair interactions, triggering ribonuclease H1-
mediated degradation of the target mRNA.6  Antisense oligonucleotide-mediated 
selective reduction of HTT mRNA leads to lowered HTT levels and sustained 
amelioration of disease-associated phenotypes in multiple transgenic animal models of 
HD.7  Chronic administration of HTT-lowering agents to wild-type non-human primates  
results in HTT reduction in central nervous system (CNS) tissues without adverse 
effects.7,8  Experiments with alternative modalities designed to inhibit HTT expression 
yield similar effects in animal models of HD8-10, validating HTT reduction as a potentially 
 viable disease-modifying therapeutic strategy.  We report the results of a targeted HTT-
lowering agent, in this Phase 1/2a clinical study of bolus intrathecally-administered HTT-
targeting antisense oligonucleotide in adults with early HD.   
 Methods 
Study drug 
HTTRx is a chemically modified synthetic oligomer that is perfectly complementary to a 
20-nucleotide stretch of HTT mRNA.  HTTRx binds to HTT mRNA through Watson-Crick 
base pairing, with hybridization resulting in endogenous ribonuclease H1-mediated 
degradation of the HTT mRNA, inhibiting translation of the huntingtin protein.  The 
sequence of HTTRx is (5’ to 3’) ccotocoaogTAACATTGACaococoac, where capital letters 
represent 2’-deoxyribose nucleosides, and small letters 2’-(2-methoxyethyl)ribose 
nucleosides.  Nucleoside linkages represented with a subscript o are phosphodiester, 
and all others are phosphorothioate.  Letters represent adenine, 5-methylcytosine, 
guanine, and thymine nucleobases.    
Study oversight 
The study was conducted in accordance with the Declaration of Helsinki. The 
study protocol and all documentation were approved by the institutional review board or 
independent ethics committee at each investigational site. All patients provided written, 
informed consent. The study was sponsored by Ionis Pharmaceuticals, which provided 
the study medication (HTTRx and placebo). Personnel from Ionis designed the study in 
conjunction with collaborators from F. Hoffmann-La Roche Ltd, principal academic 
investigators and other disease experts.  An independent data safety monitoring board 
authorized each dose escalation after unblinded review of safety data and consultation 
with the sponsor. The investigators collected the data, which was held and maintained 
by Ionis.  Data were analyzed by personnel from Ionis and were interpreted by all 
 authors.  The investigators vouch for the fidelity of the study to the protocol and protocol 
amendments.  The authors vouch for the completeness and accuracy of the data. The 
authors and sponsor made the decision to submit the manuscript for publication.   
Patients 
Eligible participants were between the ages of 25 and 65 and had early manifest 
disease, defined by 36 or more CAG repeats in the HTT gene and clinical stage 1 
disease (Unified Huntington’s Disease Rating Scale total functional capacity scores of 
11-13, where scores can range from 0 to 13 and 11-13 represents little to no functional 
impairment across the items assessed – occupation, finances, domestic chores, 
activities of daily living and care level).11  Further details of the inclusion and exclusion 
criteria are provided in the Supplementary Appendix. 
Study design and objectives 
HTTRx-CS1 was a randomized, double-blinded, placebo-controlled, multi-center, Phase 
1/2a, first-in-human study, performed at 9 centers in UK, Germany and Canada from 
August 2015 to November 2017.  A centralized automated randomization system was 
used to assign patients in the ratio 3:1 to HTTRx or placebo within each of 5 dosing 
cohorts in an ascending-dose design (10 mg, 30 mg, 60 mg, 90 mg or 120 mg).  Each 
participant received 4 bolus intrathecal injections of HTTRx or placebo (artificial 
cerebrospinal fluid) at 4-week intervals followed by a 4-month untreated follow-up 
period.  A cerebrospinal fluid (CSF) sample was collected prior to each study drug 
administration and either 4 or 8 weeks after the last dose of study drug (Figure 1.)  
 Investigators, participants, and sponsor were unaware of the treatment assignments for 
the duration of the study.   
The primary objective was evaluation of the safety and tolerability of HTTRx.  
Safety evaluations included physical examination, neurologic examination, Columbia-
Suicide Severity Rating Scale, laboratory assessments, vital signs, electrocardiogram 
and safety neuroimaging sequences.  At each study visit, participants were queried for 
other changes in health status in an open ended fashion.   
The secondary objective was characterization of CSF pharmacokinetics of 
HTTRx.  Exploratory objectives were characterization of plasma pharmacokinetics of 
HTTRx and exploration of the effects of HTTRx on pharmacodynamic biomarkers and 
clinical endpoints relevant in HD, including the concentrations of mutant huntingtin 
protein (mHTT) and neurofilament light protein in the CSF, ventricular volume and HD 
Cognitive Battery composite cognitive score.  After the completion of the study, 
participants were offered the opportunity to enroll in a 15-month, open-label extension 
study (NCT03342053) evaluating the effects of either monthly or every other month 
intrathecal administration of 120 mg HTTRx.  
Measurement of Cerebral Volume 
3-Tesla T1-weighted structural brain MR scans were obtained and transferred to an 
independent image analysis provider where quality-control, processing and volumetric 
analysis were performed, blinded to treatment status, according to established 
methods.12  Whole brain and regional volume changes were calculated using the 
 boundary shift integral, a semi-automated method that determines volume change from 
three-dimensional shift between paired images of a region’s boundary.  
 
Statistical analysis 
The primary objective of the study was evaluation of safety.  Treatment-emergent 
adverse events (AE), serious AEs, laboratory tests (blood and CSF), vital signs, ECG 
measures and observations from the Columbia Suicide Severity Rating Scale (C-SSRS) 
were summarized by treatment group.  Where possible, pharmacokinetic parameters 
were assessed for HTTRx in CSF (secondary objective) and plasma (exploratory 
objective).  Analyses of pharmacodynamic biomarkers and clinical endpoints were 
summarized by treatment group, and the HTTRx-treated groups were compared to 
placebo.  The treatment differences and 95% confidence intervals (CIs) for changes in 
CSF mHTT were Hodges-Lehmann estimations based on Wilcoxon Rank Sum Test or 
obtained using ANOVA, depending on the normality of the data.  Relationships between 
CSF mHTT reduction and clinical outcomes were explored in a post-hoc setting using 
the Spearman correlation coefficient, and the 95% CI of the correlation coefficient was 
based on Fisher’s z transformation.  Due to the exploratory nature of this study, 
adjustments for multiplicity of testing were not used.  Interpretation of HTTRx effects on 
tissue mHTT is based on the extent of reduction of mHTT reduction in the CSF and a 
linked pharmacokinetic/pharmacodynamic clearance model based on data collected in 
human mHTT transgenic mice and non-human primate (details provided in the 
Supplementary Appendix). 
  
 Results 
Patients 
From August 2015 through April 2017, 52 patients were screened for eligibility and 46 
patients underwent randomization according to the protocol.  All patients received all 
scheduled doses of assigned treatment, and all randomized patients completed the 
study according to the protocol. (Patient flow diagram is provided as Supplementary 
Appendix Figure S3.)  The baseline characteristics were representative of early-stage 
Huntington’s disease and were similar across the treatment groups (Table 1).  
Primary Objective -- Safety and Tolerability 
The incidence of adverse events (AEs) was similar in patients receiving HTTRx and 
patients receiving placebo (Table 2).  All events were mild or moderate in severity.  The 
most commonly reported AEs in HTTRx-treated patients were procedural pain and post-
dural puncture headache, which occurred after approximately 10% of lumbar punctures 
and had no apparent relationship to study duration or dose.  There was no evidence for 
increased risk of post-dural puncture headache with successive lumbar punctures.  All 
post-dural puncture headaches resolved (median duration of 2 days), and no blood 
patches were required.  Very few AEs (6%) were considered related to study drug, and 
most related events (83%) were also considered related to study procedure.  There 
were no deaths, dose-limiting AEs, treatment discontinuations or treatment delays 
during the study.  The only serious AE was an inpatient admission of a patient in the 
placebo group with for observation of a mild post-dural puncture headache.  Neither 
suicidal behavior nor serious suicidal ideation emerged in any patient during the study.  
 One case of mildly increased CSF leukocyte count (20-23 cells/mm3, measured in 
triplicate) without associated symptoms was observed 8 weeks after last dose of 60 mg 
HTTRx; clinical safety MRI and EEG were normal.  The asymptomatic elevation 
persisted throughout the post-treatment period and resolved prior to the patient’s 
initiation of treatment in the extension study, 64 weeks after last dose in this study. 
Secondary Objective  
HTTRx was measurable in the CSF of most patients receiving doses of 30 mg or more.  
Trough concentrations increased with increasing dose from below the limit of 
quantification at the 10 mg dose through the 60 mg dose with a plateau in CSF 
concentration beyond 60 mg (Figure 2A).  No accumulation was observed in CSF over 
time.   
Exploratory Objectives  
Plasma Concentrations of HTTRx 
Median peak plasma concentrations were reached within 4 hours after bolus intrathecal 
administration and declined to less than 30% of peak concentration by 24 hours after 
dosing.  HTTRx concentration in plasma increased approximately dose-proportionally 
over the explored dose range (Figure 2B), without evidence of plasma concentration 
accumulation 24 hours post-dose over the course of the study and a minor increase 
(<20%) in peak concentration at the 120 mg dose level. 
Concentrations of mHTT in the Cerebrospinal Fluid 
 After four doses of HTTRx at 1 month intervals there were dose-dependent decreases in 
CSF mHTT concentration versus placebo, with maximal individual reduction of 63% and 
approximately 40% mean reduction for the 90- and 120-mg dose cohorts (Figure 3A, B; 
Table S1).  Steady state maximal reduction of CSF mHTT does not appear to have 
been reached during the 3-month dosing period (Figure 3A,C).     
Clinical Outcomes  
Functional, cognitive, psychiatric and neurologic clinical outcomes were generally 
unchanged at the dose-group level during the study, and no differences were observed 
between placebo-treated patients and patients who received HTTRx, regardless of dose. 
(See Supplementary Appendix, Table S2.)   
Ventricular volume exhibited dose- and time-dependent increases at Day 113 and at 
Day 197, without adverse consequences, in the 90-mg and 120-mg dose groups 
compared to the placebo group (boundary shift intervals of 2.6 and 5.0 mL for the 90-
mg group and 2.3 and 5.3 mL for the 120-mg group at Days 113 and 197, respectively).  
Elevations of the neurofilament light protein in the CSF occurred in some high-dose 
patients at Day 113 or 141 (i.e., one or two months after cessation of dosing, 
respectively) without associated adverse events or safety MRI changes.  (See 
Supplementary Appendix Figure S4.)  By the start of the extension study (7-27 months 
since final doses in this study), levels of the neurofilament light protein in the CSF had 
generally returned to pre-study levels; during the extension study they rose with a 
similar time course and magnitude as observed in this study and then decreased at later 
timepoints despite continued treatment (unpublished data).   
 Post-hoc Analyses 
In parallel with this study, the composite Unified Huntington Disease Rating Scale 
(cUHDRS) was developed to serve as a measure of clinical progression in stage I and II 
HD.13  We examined the relationships between the degree of CSF mHTT lowering and 
changes in the cUHDRS and its four components and observed correlations between 
reduction in CSF mHTT and improvements in cUHDRS and two of its components 
(Supplementary Appendix Figure S5). These correlations should be interpreted with 
caution, because the tests were not prespecified, nor the coefficients of correlation 
adjusted for multiple testing.   
 Discussion 
Four repeated monthly bolus intrathecal administration of HTTRx, an HTT mRNA-
targeting antisense oligonucleotide, to adults with early HD was not accompanied by 
any serious adverse events. The intervention achieved a dose-dependent reduction of 
mHTT, the protein that putatively causes HD, in the CSF.  Based only on this study, we 
do not know whether this reduction reflects a reduction of mHTT in the CNS, although 
preclinical studies support the hypothesis that CSF mHTT levels reflect CNS tissue 
mHTT level (Supplemental Appendix and Southwell et al.14).  While the positive effects 
of sustained lowering of mHTT on motor function and survival in mouse models of HD7,8 
provided a rationale for development of an HTT-targeting antisense oligonucleotide, 
larger studies of greater duration are needed to determine whether HTTRx-mediated 
reduction of mHTT in the CSF is associated with a treatment effect on disease course, 
 which is typically slow, with changes on standard outcomes generally occurring over 
years.   
Ventricular volume exhibited apparent dose- and time-dependent increases 
during the study without corresponding changes in whole brain volume.  Slow, 
progressive whole brain atrophy (i.e., irreversible loss of brain tissue) and ventricular 
expansion are characteristic features of HD,15 and neuroinflammation is a known 
phenomenon in HD.16,17 Although “pseudoatrophy” (i.e., ventricular expansion due to 
resolution of inflammatory edema and gliosis) has been described in clinical studies of 
multiple sclerosis and Alzheimer’s disease, it has been a challenge to differentiate 
between treatment-induced pseudoatrophy and disease-related atrophy,18-23  and we 
have not assessed the effect of HTTRx treatment on inflammation or gliosis has been 
conducted in humans or animal models.  
The putative neuronal injury marker, the neurofilament light protein in the CSF,24 
exhibited apparent dose- and time-dependent increases during the study, and reversed 
after cessation of study treatment and also after transient increases during the 
extension study. To our knowledge, there are no published longitudinal studies of 
neurofilament light protein in the CSF of persons with HD and so the magnitude of 
increase that corresponds with an adverse outcome is unknown. The values observed 
in this study are within the range observed in a cross-sectional study of HD patients.25   
In sum, we have shown that the antisense oligonucleotide drug HTTRx reduces 
mHTT in the CSF of persons with HD.  More generally, we have demonstrated 
 antisense-mediated protein suppression in the central nervous system of patients with a 
neurodegenerative disease.   
Disclosure forms provided by the authors are available with the full text of this article at 
NEJM.org. 
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 Figure Legends 
Figure 1.  Study design.  At the conclusion of the screening period, eligible patients 
were randomized 3:1 to HTTRx or placebo.  CSF was collected prior to study drug 
administration on Days 1, 29, 57 and 85; the CSF sample on Day 1 serves as a 
baseline sample, and CSF samples on Days 29, 57 and 85 serve as 28-day post-dose 
trough samples.  In each patient, one sample was collected after completion of dosing, 
either on Day 113 or Day 141 according to randomized assignment.  CSF collection on 
Day 113 serves as a 28-day post-last-dose sample; CSF collection on Day 141 serves 
as a 56-day post-last-dose sample.  Dotted lines indicate the relationship between each 
dose and the subsequent CSF sample. 
 
Figure 2.  HTTRx exposure (A) Maximum pre-dose (i.e., 28-day trough) HTTRx 
concentration in CSF by dose group.  (B) Mean ± SEM HTTRx concentration in plasma 
by dose group over the 24-hour periods after the first dose (left) and fourth dose (right).  
See Supplemental Appendix for further discussion of observed HTTRx concentrations. 
 
Figure 3.  Effect of HTTRx on CSF mHTT concentrations (A) CSF mHTT levels over 
time (absolute values in fM, top; percent change from baseline, bottom) for individual 
patients in each dose group. Arrowheads indicate dosing days.  See Supplemental 
Appendix for a discussion of individual patient data observed in the 120mg dose group.  
(B) CSF mHTT percent change from baseline to last available 28-day post-dose 
timepoint (i.e., either Study Day 113 for patients who underwent CSF sampling at Study 
Day 113 or Study Day 85 for patients who did not) for individual patients (circles) and 
 dose group means (horizontal lines). (C) Mean ± SD absolute change (left) and 
percentage change from baseline over time by dose group.  Arrowheads indicate dosing 
days.  As shown by dotted lines and as illustrated in Figure 1, Day 113 and Day 141 
samples were each performed in a randomized subset of patients. 
 
 Tables 
Table 1. Patient characteristics at baseline 
 
Placebo 
(n=12) 
HTTRx, 
all 
(n=34) 
HTTRx, 
10mg 
(n=3) 
HTTRx, 
30mg 
(n=6) 
HTTRx, 
60mg 
(n=6) 
HTTRx, 
90mg 
(n=9) 
HTTRx, 
120mg 
(n=10) 
Age, yr 49±10 46±10 44±17 53±7 43±11 46±10 45±10 
Female sex, no. 
(%) 
4 (33) 14 (41) 1 (33) 1 (17) 3 (50) 3 (33) 6 (60) 
White race, no. 
(%) 
11 (92) 32 (94) 3 (100) 5 (83) 6 (100) 9 (100) 9 (90) 
CAG repeat 
length 
44±2 44±3 46±6 43±2 45±2 44±3 45±4 
MoCA score 25±2 26±3 26±4 27±2 26±3 26±3 26±3 
TFC score, no. 
(%) 
     11 
     12 
     13 
 
6 (50) 
4 (33) 
2 (17) 
 
9 (26) 
15 (44) 
10 (29) 
 
0 (0) 
1 (33) 
2 (67) 
 
2 (33) 
4 (67) 
0 (0) 
 
2 (33) 
3 (50) 
1 (17) 
 
2 (22) 
4 (44) 
3 (33) 
 
3 (30) 
3 (30) 
4 (40) 
TMS 24±7 22±10 21±7 20±13 25±13 22±10 21±9 
Independence 
Scale 
89±8 
90±8 93±6 88±11 86±8 93±8 90±6 
Disease burden 
score 
398.4±50
.1 
383.7±66.
0 
385.2±109
.1 
366.7±50
.8 
383.8±34
.3 
364.5±68
.7 
410.8±75
.1 
 Values with ± are mean ± SD; TFC, Unified Huntington’s Disease Rating Scale Total 
Functional Capacity; MoCA, Montreal cognitive assessment; TMS, total motor score; 
disease burden score (calculated by [CAG repeat length - 35.5] * age in years) 26; 
mHTT, mutant huntingtin protein concentration. 
 
  
mHTT in CSF, 
fM 
109±43 110±46 144±50 120±45 117±30 105±65 96±35 
 Table 2. Treatment-emergent adverse events reported in 3 or more patients in the 
HTTRx groups* 
 
 
Grade 1 Grade 2 Grade 3/4 
HTTRx 
Groups  
(N = 34)  
n (%) 
Placebo 
Group 
(N = 12) 
n (%) 
HTTRx 
Groups  
(N = 34)  
n (%) 
Placebo 
Group 
(N = 12) 
n (%) 
HTTRx 
Groups  
(N = 34)  
n (%) 
Placebo 
Group 
(N = 12) 
n (%) 
Any adverse event 20 (58.8) 7 (58.3) 13 (38.2) 5 (41.7) 0 0 
Any serious adverse event 0 1 (8.3) 0 0 0 0 
System Organ Class 
       Preferred Term 
Injury, poisoning and procedural 
complications 
19 (55.9) 7 (58.3) 7 (20.6) 4 (33.3) 0 0 
 Procedural pain 17 (50.0) 4 (33.3) 2 (5.9) 2 (16.7) 0 0 
 Post lumbar puncture syndrome 8 (23.5) 4 (33.3) 4 (11.8) 1 (8.3) 0 0 
 Fall 7 (20.6) 2 (16.7) 0 1 (8.3) 0 0 
 Skin abrasion 5 (14.7) 1 (8.3) 0 0 0 0 
Infections and infestations 21 (61.8) 4 (33.3) 2 (5.9) 2 (16.7) 0 0 
 Nasopharyngitis 7 (20.6) 0 0 2 (16.7) 0 0 
 Upper respiratory tract infection 3 (8.8) 1 (8.3) 1 (2.9) 0 0 0 
 Bronchitis 2 (5.9) 0 1 (2.9) 0 0 0 
 Influenza 2 (5.9) 0 1 (2.9) 0 0 0 
 Rhinovirus infection 3 (8.8) 0 0 0 0 0 
Nervous system disorders 9 (26.5) 4 (33.3) 3 (8.8) 3 (25.0) 0 0 
 Headache 4 (11.8) 3 (25.0) 2 (5.9) 3 (25.0) 0 0 
 Hypoesthesia 3 (8.8) 0 0 0 0 0 
Musculoskeletal and connective 
tissue disorders 
9 (26.5) 4 (33.3) 1 (2.9) 1 (8.3) 0 0 
 Arthralgia 4 (11.8) 2 (16.7) 0 0 0 0 
 Back pain 3 (8.8) 1 (8.3) 1 (2.9) 0 0 0 
General disorders and administration 
site conditions 
5 (14.7) 2 (16.7) 1 (2.9) 0 0 0 
 Fatigue 4 (11.8) 0 1 (2.9) 0 0 0 
Gastrointestinal disorders 5 (14.7) 1 (8.3) 1 (2.9) 0 0 0 
 Toothache 2 (5.9) 0 1 (2.9) 0 0 0 
Vascular disorders 3 (8.8) 0 0 0 0 0 
 Hematoma 3 (8.8) 0 0 0 0 0 
 * Each adverse event was rated as mild, moderate or severe, corresponding to grade 1, 
2 or 3, respectively.  In addition, serious adverse events were rated as life-threatening 
(grade 4) or not life-threatening.  At each level of summation (overall, System Organ 
Class, Preferred Term), patients reporting more than one adverse event are counted 
only once using the most severe category. 
 
 
 
  
  
 
 
 
 
  
  
  
 
 
  
  
 
 
